L152
For the first time, one of the new immunotherapy drugs has shown promise against breast cancer in a large study that combined it with chemotherapy to treat an aggressive form of the disease. But the benefit for most women was small, Immunotherapy Shows Modest Progress Against Breast Cancer
raising questions about whether the treatment is worth its high cost and side effects.
Results were discussed Saturday at a cancer conference in Munich and published by the New England Journal of Medicine.
Drugs called checkpoint inhibitors have transformed treatment of many types of cancer by removing a chemical brake that keeps the immune system from killing tumor cells. Their discovery recently earned scientists a Nobel Prize. Until now, though, they haven’t proved valuable against breast cancer.
The new study tested one from Roche called Tecentriq plus chemo versus chemo alone in 902 women with advanced triple-negative breast cancer. About 15 percent of cases are this type, their growth is not fueled by the hormones estrogen or progesterone, or the gene that Herceptin targets, making them hard to treat.
Women in the study who received Tecentriq plus chemo went two months longer on average without their cancer worsening compared with those on chemo alone, a modest benefit. The combo did not significantly improve survival in an early look before long-term follow-up is complete.
Previous studies found that immunotherapies work best in patients with high levels of a protein that the drugs target, and the plan for the breast cancer study called for analyzing how women fared according to that factor if Tecentriq improved survival overall.
The drug failed that test, but researchers still looked at protein-level results and saw encouraging signs. Women with high levels who received the combo treatment lived roughly 25 months on average versus about 15 months for women given chemo alone.
That’s a big difference, but it will take more time to see if there’s a reliable way to predict benefit, said Dr. Jennifer Litton of the MD Anderson Cancer Center in Houston. She had no role in running the study but enrolled some patients in it and oversees 14 others testing immunotherapies.
“We’re really hopeful that we can identify a group of women who can get a much bigger and longer response,” she said.
Another breast cancer specialist with no role in the study, Dr. Michael Hassett at Dana-Farber Cancer Institute in Boston, said he felt “cautious excitement” that immunotherapy may prove helpful for certain breast cancer patients.
Side effects need a close look, both doctors said. Nearly all study participants had typical chemo side effects such as nausea or low blood cell counts, but serious ones were more common with the combo treatment and twice as many women on it stopped treatment for that reason.
Three of the six deaths from side effects in the combo group were blamed on the treatment itself; only one of three such deaths in the chemo group was.
Cost is another concern. Tecentriq is $12,500 a month. The chemo in this study was Celgene’s Abraxane, which costs about $3,000 per dose plus doctor fees for the IV treatments. Older chemo drugs cost less but require patients to use a steroid to prevent allergic reactions that might interfere with the immunotherapy. Abraxane was chosen because it avoids the need for a steroid, said one study leader, Dr. Sylvia Adams of NYU Langone Health.
The study was sponsored by Roche and many study leaders consult or work for the company or own stock in it.
L152的更多相关文章
- WPF的"路径标记语法"
在此之前我们先了解一下WPF的"路径标记语法" M:表示绘制起点 // M 0,0 L:表示绘制直线 (H:横线 V:竖线) // L 100,0 C:三次方贝塞尔曲线 // ...
- Beego源码分析(转)
摘要 beego 是 @astaxie 开发的重量级Go语言Web框架.它有标准的MVC模式,完善的功能模块,和优异的调试和开发模式等特点.并且beego在国内企业用户较多,社区发达和Q群,文档齐全, ...
- 详解WPF Blend工具中的复合路径功能 ( 含路径标记语法 )
写此文章的目的是为了简单分析一下 Blend工具中提供的"复合路径"功能.有人在我的博文中留言问我复合路径的问题. 稍微琢磨一下,觉得应该是对的.因此贴出来和大家分享.有不对的说 ...
- CoreCLR源码探索(二) new是什么
前一篇我们看到了CoreCLR中对Object的定义,这一篇我们将会看CoreCLR中对new的定义和处理 new对于.Net程序员们来说同样是耳熟能详的关键词,我们每天都会用到new,然而new究竟 ...
- Linux进程退出详解(do_exit)--Linux进程的管理与调度(十四)
Linux进程的退出 linux下进程退出的方式 正常退出 从main函数返回return 调用exit 调用_exit 异常退出 调用abort 由信号终止 _exit, exit和_Exit的区别 ...
- kafka-producer配置
kafka-producer版本对比 Kafka的producer的API根据版本的不同分为kafka0.8.1.X之前的 kafka.javaapi.producer.Producer.以及之后版本 ...
- 动态svg效果
import React from 'react'; import TweenOne from 'rc-tween-one'; import SvgDrawPlugin from 'rc-tween- ...
- [转载]amba_device使用分析
什么是AMBA? ---AMBA是一个片内总线规范. ARM官网的介绍:http://infocenter.arm.com/help/index.jsp?topic=/com.arm.doc.ddi0 ...
- CoreCLR源码2
CoreCLR源码 前一篇我们看到了CoreCLR中对Object的定义,这一篇我们将会看CoreCLR中对new的定义和处理new对于.Net程序员们来说同样是耳熟能详的关键词,我们每天都会用到ne ...
随机推荐
- Python Date 1–Hello world print
对比学习Python与C str1 = 'hello python 2'# 字符串i = 3.1415926535 print(str1)print("hello python\n" ...
- 前端学习笔记之BOM和DOM
前言 到目前为止,我们已经学过了JavaScript的一些简单的语法.但是这些简单的语法,并没有和浏览器有任何交互. 也就是我们还不能制作一些我们经常看到的网页的一些交互,我们需要继续学习BOM和DO ...
- 根据iframe获取window
今天使用layui弹出窗口,需要将函数写在弹出的窗口,但是按钮事件是在父层窗口绑定的,这样就要在父层窗口调用子层窗口的函数. 子层函数与父层函数 function topup() { console. ...
- CSS Pseudo-classes(伪类)
CSS Pseudo-classes(伪类) CSS伪类是用来添加一些选择器的特殊效果. 一.语法 伪类的语法: selector:pseudo-class {property:value;} CSS ...
- hadoop namenode HA集群搭建
hadoop集群搭建(namenode是单点的) http://www.cnblogs.com/kisf/p/7456290.html HA集群需要zk, zk搭建:http://www.cnblo ...
- Commons Configuration之一简介
转载自(https://my.oschina.net/u/2000201/blog/486327) 1 简介 Commons Configuration软件类库提供通用配置接口,使Java应用程 ...
- 1970年1月1日(00:00:00 GMT)Unix 时间戳(Unix Timestamp)
转载自(http://jm.ncxyol.com/post-88.html) 今天在看Python API时,看到time模块: The epoch is the point where the ...
- rhel7配置链路聚合(双网卡热备)
team方法 1). nmcli connection add type team con-name team0 ifname team0 config '{"runer":{&q ...
- 在使用Vue.js中使用axios库时,遇到415错误(不支持的媒体类型(Unsupported media type))
知识点:vue2.0中使用axios进行(put,post请求时),遇到415错误 解决办法:在axios的第三个参数config中,设置请求头信息'Content-Type': 'applicati ...
- matplotlib 初步学习
author:pprp Matplotlib数据可视化 [TOC] 安装 conda install matplotlib sudo apt-get install python-matplotlib ...